English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, January 21, 2022
エーザイ、「世界で最も持続可能な100社」に6回目の選定
Thursday, January 20, 2022
エーザイ、「レンビマ(R)」と「キイトルーダ(R)」の併用療法について進行性子宮内膜がんを対象とした臨床第III相309試験/KEYNOTE-775試験の結果がthe New England Journal of Medicineに掲載
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Wednesday, January 19, 2022
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
エーザイ、DIAN-TUが実施する優性遺伝アルツハイマー病に対する抗MTBRタウ抗体E2814の臨床第II/III相試験に最初の被験者が登録
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
Monday, January 17, 2022
エーザイ、米国臨床腫瘍学会消化器がんシンポジウムにおいてレンバチニブに関する演題を発表
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
Thursday, January 13, 2022
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
エーザイ、ブレインパフォーマンス(脳の健康度)のセルフチェックツール「CogMate(TM)」を台湾と香港において新発売

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575